- Published on
Diagnostic Tests – Ergonovine Test
What Is the Ergonovine Test?
The ergonovine test is a specialized diagnostic procedure used in cardiology to intentionally provoke coronary vasospasm—a sudden, temporary narrowing of the coronary arteries. During this test, a medication called ergonovine is administered, usually intravenously, under controlled conditions. Ergonovine causes smooth muscle contraction, and in individuals with underlying Prinzmetal’s (variant) angina, this can trigger a brief episode of chest pain along with transient ST-segment elevation on ECG.
This controlled provocation helps clinicians determine whether chest pain is due to reversible spasm rather than fixed atherosclerotic obstruction.
When Is Ergonovine Testing the Correct Diagnostic Choice?
Ergonovine testing becomes the most useful—and often the most accurate—diagnostic test in situations where coronary artery spasm is strongly suspected. This typically involves patients who:
- Are younger than 45 years old,
- Report atypical anginal symptoms,
- Experience chest discomfort not reliably triggered by exertion, and
- Have normal or “clean” coronary arteries on cardiac catheterization.
These patients often present with episodes of chest pain occurring at rest, sometimes cyclically or at night. Because their coronary arteries do not show significant plaque buildup, vasospasm becomes the likely mechanism, and the ergonovine test can help confirm it by reproducing symptoms and ECG changes.
Treatment for Prinzmetal’s (Variant) Angina
Once coronary vasospasm is confirmed, treatment focuses on preventing future episodes by relaxing the coronary arteries and reducing the likelihood of spasm. The primary therapies include:
- Calcium channel blockers (e.g., diltiazem, amlodipine, verapamil), which reduce smooth muscle contraction and stabilize the coronary vessels.
- Nitrates (short-acting or long-acting), which provide vasodilation and rapid symptom relief when episodes occur.
In addition, avoiding triggers—such as smoking, cocaine use, or cold exposure—can help reduce the frequency of vasospastic events.
0 Comments
